OncoMatch/Clinical Trials/NCT07049055
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
Is NCT07049055 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including E-EDV-D682 and EDV-GC for pancreatic cancer, metastatic.
Treatment: E-EDV-D682 · EDV-GC · Gemcitabine · Nab paclitaxel. — The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed on therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Biomarker criteria
Required: EGFR expression
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: FOLFIRINOX or NALIRIFOX — first line for metastatic PDAC
Documented disease progression with first line FOLFIRINOX or NALIRIFOX therapy, during or within 3 months (+/- 15 days) after end of therapy.
Cannot have received: other investigational therapy
Subjects currently receiving any other investigational agent.
Cannot have received: radiotherapy
Received...radiotherapy within 21 days to receiving their first dose (or has not recovered from the toxic effects of such therapy)
Cannot have received: major surgery
Received...any major surgery within 21 days to receiving their first dose (or has not recovered from the toxic effects of such therapy)
Lab requirements
Blood counts
Adequate hematological function.
Kidney function
Adequate renal function.
Liver function
Adequate hepatic function.
Cardiac function
Adequate cardiac function with LVEF ≥ 50% at baseline.
Adequate hematological function. Adequate renal function. Adequate hepatic function. Adequate cardiac function with LVEF ≥ 50% at baseline.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Chan Soon-Shiong Institute for Medicine · El Segundo, California
- Atlantic Health · Summit, New Jersey
- Columbia University Irving Medical Center · New York, New York
- Taylor Cancer Center · Maumee, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify